LYON, France–(BUSINESS WIRE)–Regulatory News:

ERYTECH Pharma (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: ERYP), the
French biopharmaceutical company that develops innovative ‘tumor
starvation’ treatments for acute leukemia and other oncology indications
with unmet medical needs, will announce its half-year results for 2015
on Monday September 28, 2015, after market close, and hold a
presentation webcast on the September 29, 2015 at 2:30 pm CET / 8:30 am
EDT.

Erytech’s CEO, Gil Beyen, Yann Godfrin, CSO, Iman El-Hariry, CMO, and
Eric Soyer, CFO-COO, will host a conference call and webcast during
which the half-year results for 2015 and recent ERYTECH developments
will be presented, followed by a QA session.

Please dial the following numbers to participate:

USA:

 

+1 8778874163

 

United-Kingdom:

 

+44 2030432440

Switzerland:

+41 225809022

Germany:

+49 69222229031

France:

+33 172001510

Belgium:

+32 24029640

Sweden:

+46 850334664

Finland:

+358 942599700

Netherlands:

+ 31 107138194

Confirmation Code: 215991#

The webcast can be followed live online via the link: https://www.anywhereconference.com/?UserAudioMode=DATAName=Conference=135296299PIN=215991

About ERYTECH and ERY-ASP (GRASPA®): www.erytech.com

Created in Lyon, France in 2004, ERYTECH is a clinical-stage
biopharmaceutical company developing innovative therapies for rare forms
of cancer and orphan diseases. Leveraging its proprietary ERYCAPS
platform, which uses a novel technology to encapsulate therapeutic drug
substances inside red blood cells, ERYTECH has developed a pipeline of
product candidates targeting markets with high unmet medical needs.
ERYTECH’s initial focus is on the treatment of blood cancers, including
acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML), by
depriving tumors of nutrients necessary for their survival. The company
has recently announced positive efficacy and safety results from its
completed Phase 2/3 pivotal clinical trial in Europe with its lead
candidate product, ERY-ASP, also known under the trade name GRASPA®, in
children and adults with relapsed or refractory ALL. ERYTECH also has an
ongoing Phase 1 clinical trial of

ERY-ASP in the United States in adults with newly diagnosed ALL, and a
Phase 2 clinical trial in Europe evaluating GRASPA as a first-line
therapy for the treatment of elderly patients with AML, each in
combination with chemotherapy.

ERY-ASP consists of an enzyme, L-asparaginase, encapsulated inside
donor-derived red blood cells. L-asparaginase depletes asparagine, a
naturally occurring amino acid essential for the survival and
proliferation of cancer cells, from circulating blood plasma.

Every year over 50,000 patients in Europe and the United States are
diagnosed with ALL or AML. For about 80% of these patients, mainly
adults and relapsing patients, current forms of L-asparaginase cannot be
used due to their toxicity or as a result of allergic reactions. ERYTECH
believes that the safety and efficacy profile of ERY-ASP/GRASPA, as
observed in its Phase 2/3 pivotal clinical trial, offers an attractive
alternative option for the treatment of leukemia patients.

ERYTECH believes that ERY-ASP has the potential as a treatment approach
in solid tumors and is conducting a Phase 2 clinical trial in Europe in
patients with metastatic pancreatic cancer. In addition to its current
product candidates that focus on using encapsulated enzymes to induce
tumor starvation, ERYTECH is exploring the use of its platform for
developing cancer vaccines and enzyme replacement therapies.

The EMA and the US Food and Drug Administration (FDA) have granted
orphan drug designations to ERY-ASP/GRASPA for the treatment of ALL, AML
and pancreatic cancer. ERYTECH produces ERY-ASP at its own GMP-approved
and operational manufacturing site in Lyon (France), and at a site for
clinical production in Philadelphia (USA). The Company has entered into
licensing and distribution partnership agreements for ERY-ASP for ALL
and AML in Europe with Orphan Europe (Recordati Group), and for ALL in
Israel with TEVA, who will market the product under the GRASPA® brand
name.

ERYTECH is listed on Euronext regulated market in Paris (ISIN code:
FR0011471135, ticker: ERYP) and is part of the CAC Healthcare, CAC
Pharma Bio, CAC Mid Small, CAC All Tradable, EnterNext PEA-PME 150
and Next Biotech indexes. ERYTECH is also listed in the US under an ADR
level 1 program (OTC, ticker EYRYY).

Forward-looking information

This document may contain forward-looking statements and estimates with
respect to the financial position, results of operations, business
strategy, plans, objectives and anticipated future performance of
ERYTECH and of the market in which it operates. Certain of these
statements, forecasts and estimates can be recognized by the use of
words such as, without limitation, “believes”, “anticipates”, “expects”,
“intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue”
and similar expressions. They include all matters that are not
historical facts. Such statements, forecasts and estimates are based on
various assumptions and assessments of known and unknown risks,
uncertainties and other factors, which were deemed reasonable when made
but may or may not prove to be correct. Actual events are difficult to
predict and may depend upon factors that are beyond the Company’s
control. There can be no guarantees with respect to pipeline product
candidates that the candidates will receive the necessary regulatory
approvals or that they will prove to be commercially successful.
Therefore, actual results may turn out to be materially different from
the anticipated future results, performance or achievements expressed or
implied by such statements, forecasts and estimates. Documents filed by
ERYTECH Pharma with the French Autorité des Marchés Financiers (www.amf-france.org),
also available on our website (www.erytech.com)
describe such risks and uncertainties. Given these uncertainties, no
representations are made as to the accuracy or fairness of such
forward-looking statements, forecasts and estimates. Furthermore,
forward-looking statements, forecasts and estimates only speak as of the
date of the publication of this document. Readers are cautioned not to
place undue reliance on any of these forward-looking statements. ERYTECH
disclaims any obligation to update any such forward-looking statement,
forecast or estimates to reflect any change in the Company’s
expectations with regard thereto, or any change in events, conditions or
circumstances on which any such statement, forecast or estimate is
based, except to the extent required by law.